Bristol Myers Squibb Company
NEWS
BMS inked a multi-year strategic agreement with Concerto HealthAI, which focuses on oncology-specific Real-World Data (RWD) and advanced AI for Real-World Evidence (RWE) generation.
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
Today, Celgene submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its ozanimod for adults with relapsing forms of multiple sclerosis (RMS).
With some shareholder opposition raised against the $74 billion acquisition of Celgene, the BMS board of directors is attempting to strengthen support of the deal ahead of the April 12 meeting.
March is National Kidney Month, with March 14 designated as World Kidney Day. The kidneys are called the body’s chemical factories. Their job is to filter waste and perform specific important jobs like controlling red blood cell production and blood pressure.
This morning Starboard Value LP issued an investor presentation opposing the proposed deal. The group will share the materials with other shareholders in hopes to sway support for its opposition.
The American College of Cardiology (ACC) annual meeting was held this weekend in New Orleans. Here’s a look at some of the top stories that came out of the meeting.
On day two of Cowen and Company’s 39th Annual Health Care Conference, more companies shared insight into pipeline development. BioSpace rounded up a few of the stories.
Humira generated nearly $20 billion in revenue for the Illinois-based company. Celgene’s Revlimid earned about half-as-much in 2018.
JOBS
IN THE PRESS